Table 3.
Tumor characteristics.
| Men N = 294 | Women N = 218 | Overall N = 512 | Chi-squared test p-value | |
|---|---|---|---|---|
| Histology - n (%) | 0.2677A | |||
| Adenocarcinoma | 249 (84.7) | 192 (88.1) | 441 (86.1) | |
| Mucoid adenocarcinoma | 42 (14.3) | 23 (10.6) | 65 (12.7) | |
| Ring cell carcinoma | 1 (0.3) | 2 (0.9) | 3 (0.6) | |
| Medullary carcinoma | 2 (0.7) | 0 (0.0) | 2 (0.4) | |
| Other | 0 (0.0) | 1 (0.5) | 1 (0.2) | |
| Histology categorization - n (%) | 0.4324A | |||
| Adenocarcinoma | 249 (84.7) | 192 (88.1) | 441 (86.1) | |
| Mucoid adenocarcinoma | 42 (14.3) | 23 (10.6) | 65 (12.7) | |
| Other | 3 (1.0) | 3 (1.4) | 6 (1.2) | |
| T stage - n (%) | 0.9437 | |||
| Tx | 1 (0.3) | 0 (0.0) | 1 (0.2) | |
| T1 | 6 (2.0) | 6 (2.8) | 12 (2.3) | |
| T2a | 8 (2.7) | 7 (3.2) | 15 (2.9) | |
| T2b | 9 (3.1) | 7 (3.2) | 16 (3.1) | |
| T3 | 221 (75.2) | 164 (75.2) | 385 (75.2) | |
| T4 | 49 (16.7) | 34 (15.6) | 83 (16.2) | |
| N stage - n (%) | 0.3398 | |||
| N0 | 100 (34.0) | 85 (39.0) | 185 (36.1) | |
| N1 | 137 (46.6) | 100 (45.9) | 237 (46.3) | |
| N2 | 57 (19.4) | 33 (15.1) | 90 (17.6) | |
| Clinical stage - n (%) | 0.2464 | |||
| II | 100 (34.0) | 85 (39.0) | 185 (36.1) | |
| III | 194 (66.0) | 133 (61.0) | 327 (63.9) | |
| Clinical stage subgrups - n (%) | 0.2734 | |||
| II | 100 (34.0) | 85 (39.0) | 185 (36.1) | |
| III low risk | 121 (41.2) | 91 (41.7) | 212 (41.4) | |
| III high risk | 73 (24.8) | 42 (19.3) | 115 (22.5) | |
| Grade - n (%) | 0.3639A | |||
| GX | 1 (0.3) | 3 (1.4) | 4 (0.8) | |
| G1 | 25 (8.6) | 13 (6.0) | 38 (7.5) | |
| G2 | 172 (59.1) | 135 (62.5) | 307 (60.6) | |
| G3 | 93 (32.0) | 65 (30.1) | 158 (31.2) | |
| Missing | 3 | 2 | 5 | |
| Chemotherapy taken during the TOSCA trial - n (%) | 0.6404 | |||
| Folfox-4 (6 months) | 100 (34.0) | 86 (39.4) | 186 (36.3) | |
| Xelox (24 weeks) | 43 (14.6) | 28 (12.8) | 71 (13.9) | |
| Folfox-4 (3 months) | 110 (37.4) | 77 (35.3) | 187 (36.5) | |
| Xelox (12 weeks) | 41 (13.9) | 27 (12.4) | 68 (13.3) |
AFisher test p-value.